Tech Company Financing Transactions
KaloBios Pharmaceuticals Funding Round
KaloBios Pharmaceuticals secured a $20 million Series B funding round on 3/16/2005. Investors included MPM Capital, 5AM Ventures and Alloy Ventures.
Transaction Overview
Company Name
Announced On
3/16/2005
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Series B
Investors
Proceeds Purpose
We are looking forward to working with the KaloBios team and a great group of co-investors to help build a major new therapeutic antibody company.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1000 Marina Blvd. 250
Brisbane, CA 94005
USA
Brisbane, CA 94005
USA
Phone
Website
Email Address
Overview
KaloBios (NASDAQ: KBIO) is a vertically integrated therapeutic antibody company using its proprietary antibody engineering, humaneering and expression technologies for the development of a pipeline of antibody therapeutics.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Cameron Durrant
Browse more venture capital transactions:
Prev: 3/15/2005: Kazeon Systems venture capital transaction
Next: 3/16/2005: Soleil Securities Group venture capital transaction
Share this article
About Our VC Transactions Data
Our team works diligently to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs